- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06447675
Effekt- og sikkerhetsevaluering av hypertermiske bad i behandling av anfall hos barn med CDKL5-mangel
Effekt- og sikkerhetsevaluering av hypertermiske bad i behandling av anfall hos barn med CDKL5-mangel: En enkeltsenter, selvkontrollforsøk
The primary objective of this research is to study the efficacy and safety of hyperthermic baths as adjunctive therapy for reducing the frequency of seizures in CDKL5 deficiency.
Studieoversikt
Detaljert beskrivelse
This project aims to include 8 participants, and evaluate the effectiveness and safety of hyperthermic baths in patients with CDKL5 deficiency through A single-center, preliminary feasibility clinical trial. It is expected to provide new therapeutic options for patients with CDKL5 deficiency with alternative treatment options.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Kina, 100053
- Xuanwu Hospital,Capital Medical University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- A diagnosis of CDKL5 deficiency, including molecular confirmation of a pathogenic or likely pathogenic CDKL5 variant and refractory seizures
- Male or female participants aged 6 months to less than 6 years
- Parent(s) or LAR willing to give written informed consent, after being properly informed of the nature and risks of the study and prior to engaging in any study-related procedures
- Failure to control seizures despite appropriate trial of 2 or more anti-seizure medications at therapeutic doses
- Have a history of at least 8 countable seizures per 4 weeks during the 8 weeks prior to screening. Countable seizures will be defined by the following:Seizures with or without impairment of consciousness with a clear motor component, including generalized tonic-clonic, focal to bilateral tonic-clonic, atonic, bilateral clonic, bilateral tonic, focal motor seizures with or without impaired awareness, or infantile spasms. Clusters of infantile spasms/tonic seizures will be counted as a single seizure.
- Participants should be on a stable regimen of anti-seizure medications for ≥ 4 weeks prior to the screening visit, without a foreseeable change in dosing for the duration of the DB phase.
- Vagus nerve stimulator (VNS) are permitted, but should be implanted for 1 year prior to screening and settings should be unchanged throughout the study.
- Parent/caregiver is able and willing to maintain an accurate and complete daily seizure eDiary for the duration of the study.
Exclusion Criteria:
- Any history of previous brain disease (trauma, etc.) that likely to precipitate seizures.
- Tissue damage (eczema, etc.) in the area where hyperthermic baths will be applied on the skin.
- Seizures associated with hyperthermic baths.
- Presence of any clinical condition that in the opinion of the principal investigator makes the patient not suitable to participate in the trial.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Hyperthermic Baths
Patients with CDKL5 deficiency assigned to hyperthermic baths will have their body immersed in a hot water (40~42°C) bath for 20 min per session. |
The intervention will consist of 12 weeks of repeated, daily 20-min body immersions. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Seizure frequency (SF28)
Tidsramme: Up to 12 week after hyperthermic baths
|
Seizure frequency (SF28) is defined as seizure count per month (28-day) period. The SF28 is calculated as follows, where D=total number of days for which seizure information is collected for the specific 28-day interval: SF28=(Total number of seizures in D days/D)*28. In addition, the baseline seizure frequency is defined as SF28 in the baseline period. The seizure frequency in the treatment phase is defined as SF28 per month during the treatment period. Percent change in seizure frequency=100*(treatment SF28-baseline SF28)/baseline SF28. |
Up to 12 week after hyperthermic baths
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Seizure Responder Rate
Tidsramme: Up to 12 week after hyperthermic baths
|
The proportion of patients with a ≥ 25%, ≥50% reduction from Baseline in seizure frequency. |
Up to 12 week after hyperthermic baths
|
|
Seizure-free Days
Tidsramme: Up to 12 week after hyperthermic baths
|
Seizure-free days over the entire treatment phase |
Up to 12 week after hyperthermic baths
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Liankun Ren, MD, Xuanwu Hospital, Beijing
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2024-111-002
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .